FDA warns of interference between CT imaging and electronic medical devices

The FDA issued a safety alert on March 31 announcing that it had received a small number of adverse events that it believes are associated with CT imaging of insulin pumps, cardiac implantable electronic devices (pacemakers and implantable cardioverter defibrillators) and neurostimulators.

“Our current understanding is that when a CT scanner directly irradiates the circuitry of certain implantable or wearable electronic medical devices (i.e. when the device is visible in the resulting CT image), it can cause sufficient electronic interference to affect the function and operation of the medical device,” the FDA said.

However, the agency said there was an “extremely low” probability that the interference could cause clinically significant adverse events.

Further, operators can avoid interference by making sure the medical device is outside the CT scanner’s primary X-ray beam.

The FDA noted the clinical benefits of a medically indicated CT exam outweigh the possibility of an adverse event.

“CT continues to be the preferred tomographic imaging technology for patients with implantable or wearable medical devices,” the FDA said. “CT is safer for patients with devices of unknown [MRI] safety status. You should be aware that an MR Conditional device is only safe within the MR environment that matches its conditions of safe use. Any device with an unknown MRI safety status should be assumed to be MR Unsafe.”

Tim Casey,

Executive Editor

Tim Casey joined TriMed Media Group in 2015 as Executive Editor. For the previous four years, he worked as an editor and writer for HMP Communications, primarily focused on covering managed care issues and reporting from medical and health care conferences. He was also a staff reporter at the Sacramento Bee for more than four years covering professional, college and high school sports. He earned his undergraduate degree in psychology from the University of Notre Dame and his MBA degree from Georgetown University.

Around the web

Positron, a New York-based nuclear imaging company, will now provide Upbeat Cardiology Solutions with advanced PET/CT systems and services. 

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.